#China #Shanghai #AP301 #Hyperphosphatemia #Alebund Pharmaceutical

Alebund Pharmaceuticals Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of AP301

Alebund Pharmaceuticals, a company specializing in innovative biopharmaceutical therapies, has announced a significant development in the treatment of hyperphosphatemia, a common complication in patients with chronic kidney disease (CKD). The company has successfully completed the patient enrollment phase for its global Phase III pivotal multi-regional clinical trial, branded RESPOND-2, involving the evaluation of its new phosphate binder, AP301. This trial represents a critical step forward for patients reliant on dialysis.

Understanding the Clinical Trial

The RESPOND-2 trial, which incorporates patients from both the United States and China, has been designed to assess the efficacy and safety of AP301, a fiber-iron-based phosphate binder proposed to offer improved phosphate binding capabilities without the common gastrointestinal side effects associated with current treatments. Led by U.S. Renal Care's Dr. Geoffrey A. Block, along with Professor Xiaoqiang Ding from Fudan University, the trial enrolled a total of 282 patients, significantly exceeding its original target of 264.

AP301 has been engineered to enhance patient compliance by reducing the pill burden and mitigating risks of iron overload, representing a hopeful advancement in treatment strategies for hyperphosphatemia. The trial encompasses a comprehensive study structure, including multiple phases that investigate dose responses and long-term therapeutic outcomes.

The Burden of Hyperphosphatemia

Hyperphosphatemia poses serious risks and complicates the management of CKD, particularly among patients on maintenance dialysis, where high serum phosphate levels can lead to vascular calcification, cardiovascular events, and other severe outcomes. Approximately95% of dialysis-dependent CKD patients experience this condition, highlighting the urgent need for effective management solutions.

Current therapeutic options, primarily oral phosphate binders, often lead to low patient compliance, which is exacerbated by undesirable side effects and the inconvenience of treatment regimens. Studies have shown alarming statistics regarding under-treatment in various countries; for instance, more than 70% of dialysis patients in China struggle to maintain phosphate levels within the desired range.

AP301: Promises and Efficacy

Data from Alebund’s prior clinical trials have shown AP301’s potential ability to manage phosphate levels effectively. In previous studies, including the completed Phase III clinical trial in China, AP301 has demonstrated non-inferiority to existing phosphate binders like sevelamer carbonate, providing significant reductions in serum phosphate levels.

Key findings indicate that after 52 weeks, patients taking AP301 exhibited higher phosphate control than those on low doses of the comparator treatment, in addition to benefitting from a lower daily requirement of the drug. Importantly, the safety profile of AP301 appears favorable with the primary adverse events being minor gastrointestinal disturbances that rarely led to treatment discontinuation.

Future Prospects

Jin Tian, M.D., Co-founder and Chief Medical Officer of Alebund, emphasized the significance of reaching this milestone in patient enrollment as a reflection of the company's commitment to advancing effective treatments for renal disease. The trial’s completion marks a pivotal point for Alebund in socio-commercial terms, setting the stage for a potential application for regulatory approval in both the U.S. and China.

The completion of the RESPOND-2 trial could pave the way for AP301’s introduction to the market, thereby providing a much-needed therapeutic option for patients suffering from hyperphosphatemia and enhancing overall treatment adherence and outcomes in CKD management.

Through its integrated approach and ongoing dedication to research and development, Alebund Pharmaceuticals is positioned to significantly impact the landscape of renal therapeutics, highlighting the importance of innovative strategies in dealing with chronic diseases like CKD. With the growing incursion of chronic kidney conditions globally, the advancements brought forth by Alebund with AP301 could represent a transformative leap in patient care and management strategies.

As the trial progresses, the nephrology community is watching closely, anticipating more positive outcomes that could further validate the efficacy of AP301 and its role in improving the quality of life for countless patients contending with hyperphosphatemia.